Oasmia Pharmaceutical AB
OASM
OASM was delisted on the 21st of August, 2019.
2 hedge funds and large institutions have $512K invested in Oasmia Pharmaceutical AB in 2016 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
40% more capital invested
Capital invested by funds: $367K → $512K (+$145K)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.91K |
OASM Hedge Fund Activity: Q4 2016 in Review
2 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q4 2016, worth a combined $512K — up 40% from $367K a quarter earlier.
Fund positioning in OASM was balanced in Q4 2016: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $178K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.91K.
- 2 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $512K of Oasmia Pharmaceutical AB stock for Q4 2016, up 40% quarter-over-quarter.
- 0 funds opened new Oasmia Pharmaceutical AB positions in Q4 2016 and 0 closed out.
- The largest Oasmia Pharmaceutical AB buyer in Q4 2016 was Sio Capital Management, an estimated $178K added.
- The largest Oasmia Pharmaceutical AB seller in Q4 2016 was Tower Research Capital (TRC), an estimated $1.91K sold.
Based on aggregated 13F filings for Q4 2016.